Novartis gains access to Dunad’s non-E3 protein degrader platform

Dunad receives $24M up front, is eligible for $1.3 billion in milestones and royalties

November 2, 2021 10:41 AM UTC

By tapping Dunad for a partnership, Novartis is gaining access to a targeted protein degradation platform that steers clear of the E3 ligase pathway and can be applied to multiple target classes.

Tuesday’s partnership between Dunad Therapeutics Ltd. and Novartis AG (SIX:NOVN; NYSE:NVS) covers four targets. The pharma will gain an exclusive option to license, develop and commercialize resulting candidates...